CHRISTOPHER CHANDLER: Open Payments
NPI 1972992329 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$836 in 48 payments from 13 companies in 2025. Trend: 2023 $638 · 2024 $605 · 2025 $836
Food & beverage: $836
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $179 |
| Otsuka America Pharmaceutical, Inc. | 6 | $110 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| E.R. Squibb & Sons, L.L.C. | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 2 | $60 |
| Janssen Pharmaceuticals, Inc | 2 | $43 |
| Corium, LLC | 4 | $40 |
| Janssen Scientific Affairs, LLC | 1 | $40 |
Products named: VRAYLAR, FANAPT, INVEGA SUSTENNA, Auvelity, CAPLYTA, COBENFY, AUSTEDO XR, ABILIFY ASIMTUFII.
Industry payments across ID — which companies pay providers there.
